[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100480609":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":36,"locations":47,"responsibleParty":362,"collaborators":365,"id":372,"slug":373,"hasResults":374,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":374,"sex":380,"minAge":381,"maxAge":382,"enrollmentInfo":383,"targetDuration":41,"studyType":386,"phases":387,"briefSummary":389,"conditions":390,"keywords":41,"overallStatus":50,"whyStopped":41,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":401},{"fullName":5,"class":6},"Children's Hospital Medical Center, Cincinnati","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MMFBSA","ACTIVE_COMPARATOR","MMF dosed as per body-surface area",[13],"Drug: Mycophenolate Mofetil",{"label":15,"type":16,"description":17,"interventionNames":18},"MMFPK","EXPERIMENTAL","MMF dosed as per pharmacokinetically-guided precision-dosing",[13],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Mycophenolate Mofetil","MMF dosed 600mg\u002Fm2 body surface area per dose about every 12 hours",[9],[26],"MMF dosed per body surface area",{"type":21,"name":22,"description":28,"armGroupLabels":29,"otherNames":30},"MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA \\>=60-70 mg\\*h\u002FL",[15],[31],"MMF dosed phrmacokinetically",[33],{"name":34,"affiliation":5,"role":35},"Hermine I Brunner, MD","PRINCIPAL_INVESTIGATOR",[37,43],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Angela Sr CRC","CONTACT","513-803-2118",null,"plumm@cchmc.org",{"name":44,"role":39,"phone":45,"phoneExt":41,"email":46},"Cat Clinical Research Coordinator","513-636-7299","Catherine.Robben@cchmc.org",[48,69,86,103,120,133,150,167,183,198,216,233,245,261,277,294,311,328,345],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University of California, San Francisco","RECRUITING","San Francisco","California","94518","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-122.41942,37.77493,{"lat":60,"lon":59},[63,67],{"name":64,"role":39,"phone":65,"phoneExt":41,"email":66},"Zilan Clinical Research Coordinator","(415) 353-1301","zilan.zheng@ucsf.edu",{"name":68,"role":35,"phone":41,"phoneExt":41,"email":41},"Emily von Scheven, M.D., M.A.S.",{"facility":70,"status":50,"city":71,"state":72,"zip":73,"country":54,"countryCode":55,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Children's Hospital Colorado","Aurora","Colorado","80045",{"type":57,"coordinates":75},[76,77],-104.83192,39.72943,{"lat":77,"lon":76},[80,84],{"name":81,"role":39,"phone":82,"phoneExt":41,"email":83},"Ana Clinical Research Coordinator","303-913-5450","Ana.Aristiguieta@childrenscolorado.org",{"name":85,"role":35,"phone":41,"phoneExt":41,"email":41},"Katharine Moore, MD",{"facility":87,"status":50,"city":88,"state":89,"zip":90,"country":54,"countryCode":55,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Emory Children's Center","Atlanta","Georgia","30322",{"type":57,"coordinates":92},[93,94],-84.38798,33.749,{"lat":94,"lon":93},[97,101],{"name":98,"role":39,"phone":99,"phoneExt":41,"email":100},"Heather Clinical Research Coordinator","404-712-8037","heather.jung@emory.edu",{"name":102,"role":35,"phone":41,"phoneExt":41,"email":41},"Larry Greenbaum, MD, MPH",{"facility":104,"status":50,"city":105,"state":106,"zip":107,"country":54,"countryCode":55,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Ann & Robert H. Lurie Children's Hospital of Chicago","Chicago","Illinois","60614",{"type":57,"coordinates":109},[110,111],-87.65005,41.85003,{"lat":111,"lon":110},[114,118],{"name":115,"role":39,"phone":116,"phoneExt":41,"email":117},"Gabby Clinical Research Coordinator","312-227-6277","GAMorgan@luriechildrens.org",{"name":119,"role":35,"phone":41,"phoneExt":41,"email":41},"Pooja Patel, DO",{"facility":121,"status":50,"city":105,"state":106,"zip":122,"country":54,"countryCode":55,"cosmosGeoPoint":123,"geoPoint":125,"contacts":126},"University of Chicago Medicine- Comer Children's","60637",{"type":57,"coordinates":124},[110,111],{"lat":111,"lon":110},[127,131],{"name":128,"role":39,"phone":129,"phoneExt":41,"email":130},"Melissa Director Pediatric Clinical Trials Office","773-702-2927","mmarx@bsd.uchicago.edu",{"name":132,"role":35,"phone":41,"phoneExt":41,"email":41},"Coughi Edens, MD",{"facility":134,"status":50,"city":135,"state":136,"zip":137,"country":54,"countryCode":55,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Washington University in St. Louis School of Medicine","St Louis","Missouri","63110",{"type":57,"coordinates":139},[140,141],-90.19789,38.62727,{"lat":141,"lon":140},[144,148],{"name":145,"role":39,"phone":146,"phoneExt":41,"email":147},"Joseph Clinical Research Coordinator","314-747-1349","dumayas@wustl.com",{"name":149,"role":35,"phone":41,"phoneExt":41,"email":41},"Brian Stotter, MD",{"facility":151,"status":50,"city":152,"state":153,"zip":154,"country":54,"countryCode":55,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Hackensack University Medical Center","Hackensack","New Jersey","07601",{"type":57,"coordinates":156},[157,158],-74.04347,40.88593,{"lat":158,"lon":157},[161,165],{"name":162,"role":39,"phone":163,"phoneExt":41,"email":164},"Amanda Nowakowski","551-996-3114","amanda.nowakowski@hmhn.org",{"name":166,"role":35,"phone":41,"phoneExt":41,"email":41},"Anna Carmela Gironella, MD",{"facility":168,"status":50,"city":169,"state":169,"zip":170,"country":54,"countryCode":55,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Hospital for Special Surgery","New York","10021",{"type":57,"coordinates":172},[173,174],-74.00597,40.71427,{"lat":174,"lon":173},[177,181],{"name":178,"role":39,"phone":179,"phoneExt":41,"email":180},"Julia Klauss","212-774-2703","klaussj@HSS.EDU",{"name":182,"role":35,"phone":41,"phoneExt":41,"email":41},"Karen Onel, MD",{"facility":184,"status":50,"city":169,"state":169,"zip":185,"country":54,"countryCode":55,"cosmosGeoPoint":186,"geoPoint":188,"contacts":189},"Children's Hospital at Montefiore","10467",{"type":57,"coordinates":187},[173,174],{"lat":174,"lon":173},[190,194,196],{"name":191,"role":39,"phone":192,"phoneExt":41,"email":193},"Emily Clinical Research Coordinator","718-696-2402","egillies@montefiore.org",{"name":195,"role":35,"phone":41,"phoneExt":41,"email":41},"Dawn Wahezi, MD",{"name":197,"role":35,"phone":41,"phoneExt":41,"email":41},"Beatrice Goilav, MD",{"facility":199,"status":50,"city":200,"state":201,"zip":202,"country":54,"countryCode":55,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"University of North Carolina at Chapel Hill","Chapel Hill","North Carolina","27599",{"type":57,"coordinates":204},[205,206],-79.05584,35.9132,{"lat":206,"lon":205},[209,212,214],{"name":210,"role":39,"phone":41,"phoneExt":41,"email":211},"Carolina Pastrana-Medina","carol825@med.unc.edu",{"name":213,"role":35,"phone":41,"phoneExt":41,"email":41},"Eveline Wu, MD",{"name":215,"role":35,"phone":41,"phoneExt":41,"email":41},"Laura Cannon, MD",{"facility":217,"status":50,"city":218,"state":219,"zip":220,"country":54,"countryCode":55,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"Akron Children's Hospital","Akron","Ohio","44307",{"type":57,"coordinates":222},[223,224],-81.51901,41.08144,{"lat":224,"lon":223},[227,231],{"name":228,"role":39,"phone":229,"phoneExt":41,"email":230},"Jessica Clinical Research Nurse","330-603-2234","JKracker@akronchildrens.org",{"name":232,"role":35,"phone":41,"phoneExt":41,"email":41},"Kathryn Cook, DO",{"facility":234,"status":50,"city":235,"state":219,"zip":236,"country":54,"countryCode":55,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"Cincinnati Children's Hospital Medical Center","Cincinnati","45223",{"type":57,"coordinates":238},[239,240],-84.51439,39.12711,{"lat":240,"lon":239},[243,244],{"name":44,"role":39,"phone":45,"phoneExt":41,"email":46},{"name":34,"role":35,"phone":41,"phoneExt":41,"email":41},{"facility":246,"status":50,"city":247,"state":219,"zip":248,"country":54,"countryCode":55,"cosmosGeoPoint":249,"geoPoint":253,"contacts":254},"University Hospitals Cleveland Medical Center","Cleveland","44106",{"type":57,"coordinates":250},[251,252],-81.69541,41.4995,{"lat":252,"lon":251},[255,259],{"name":256,"role":39,"phone":257,"phoneExt":41,"email":258},"Katrina Clinical Research Coordinator","216-286-7453","katrina.gogin@uhhospitals.org",{"name":260,"role":35,"phone":41,"phoneExt":41,"email":41},"R. Ezequiel Borgia, M.D M.S",{"facility":262,"status":50,"city":263,"state":219,"zip":264,"country":54,"countryCode":55,"cosmosGeoPoint":265,"geoPoint":269,"contacts":270},"Nationwide Children's Hospital","Columbus","43205",{"type":57,"coordinates":266},[267,268],-82.99879,39.96118,{"lat":268,"lon":267},[271,275],{"name":272,"role":39,"phone":273,"phoneExt":41,"email":274},"Cindy Clinical Research Nurse","614-722-0504","Cindy.Dong@nationwidechildrens.org",{"name":276,"role":35,"phone":41,"phoneExt":41,"email":41},"Stacy Ardoin, M.D., M.S.",{"facility":278,"status":50,"city":279,"state":280,"zip":281,"country":54,"countryCode":55,"cosmosGeoPoint":282,"geoPoint":286,"contacts":287},"Medical University of South Carolina","Charleston","South Carolina","29425",{"type":57,"coordinates":283},[284,285],-79.93275,32.77632,{"lat":285,"lon":284},[288,292],{"name":289,"role":39,"phone":290,"phoneExt":41,"email":291},"Susannnah Program Coordinator","843-792-8317","wakefies@musc.edu",{"name":293,"role":35,"phone":41,"phoneExt":41,"email":41},"Natasha Ruth, M.D., M.S.",{"facility":295,"status":50,"city":296,"state":297,"zip":298,"country":54,"countryCode":55,"cosmosGeoPoint":299,"geoPoint":303,"contacts":304},"Baylor College of Medicine Pediatric Immunology Allergy Rheumatology","Houston","Texas","77030",{"type":57,"coordinates":300},[301,302],-95.36327,29.76328,{"lat":302,"lon":301},[305,309],{"name":306,"role":39,"phone":307,"phoneExt":41,"email":308},"Monica Guevara","832-824-1206","Monica.Guevara@bcm.edu",{"name":310,"role":35,"phone":41,"phoneExt":41,"email":41},"Marietta DeGuzman, MD",{"facility":312,"status":50,"city":313,"state":314,"zip":315,"country":54,"countryCode":55,"cosmosGeoPoint":316,"geoPoint":320,"contacts":321},"University of Utah","Salt Lake City","Utah","84132",{"type":57,"coordinates":317},[318,319],-111.89105,40.76078,{"lat":319,"lon":318},[322,326],{"name":323,"role":39,"phone":324,"phoneExt":41,"email":325},"Suzy Clinical Research Coordinator","801-585-5067","suzy.richins@hsc.utah.edu",{"name":327,"role":35,"phone":41,"phoneExt":41,"email":41},"Aimee Hersh, MD",{"facility":329,"status":50,"city":330,"state":331,"zip":332,"country":54,"countryCode":55,"cosmosGeoPoint":333,"geoPoint":337,"contacts":338},"Seattle Children's Hospital\u002FUniversity of Washington","Seattle","Washington","98105",{"type":57,"coordinates":334},[335,336],-122.33207,47.60621,{"lat":336,"lon":335},[339,343],{"name":340,"role":39,"phone":341,"phoneExt":41,"email":342},"Megan Clinical Research Supervisor","206-200-3502","megan.kelton@seattlechildrens.org",{"name":344,"role":35,"phone":41,"phoneExt":41,"email":41},"Kristen Hayward, MD, MS",{"facility":346,"status":50,"city":347,"state":348,"zip":349,"country":54,"countryCode":55,"cosmosGeoPoint":350,"geoPoint":354,"contacts":355},"Children's Wisconsin\u002FMedical College of Wisconsin","Milwaukee","Wisconsin","53226",{"type":57,"coordinates":351},[352,353],-87.90647,43.0389,{"lat":353,"lon":352},[356,360],{"name":357,"role":39,"phone":358,"phoneExt":41,"email":359},"Nathan Clinical Research Coordinator","414-266-5662","njsimon@mcw.edu",{"name":361,"role":35,"phone":41,"phoneExt":41,"email":41},"Ellen Cody, MD",{"type":35,"investigatorFullName":363,"investigatorTitle":364,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"Hermine Brunner, MD","Division Director Rheumatology",[366,369],{"name":367,"class":368},"Genentech, Inc.","INDUSTRY",{"name":370,"class":371},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH","100480609","phase-2-the-pediatric-lupus-nephritis-mycophenolate-mofetil-plumm-study-100480609",false,"NCT05538208","The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study","Efficacy & Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis- A Double-Blind Placebo Controlled Clinical Trial","PLUMM","Inclusion\n\n1. Male or female aged 8 to \\\u003C 21 years;\n2. Must meet Classification Criteria for SLE as per the criteria of the American College of Rheumatology (ACR)\u002F European League Against Rheumatism\n3. Diagnosed with proliferative LN as per the International Society of Nephrology\u002FRenal Pathology Society4 based on kidney biopsy done within 90 days prior to enrollment into the study;\n\n   Subjects may have been previously diagnosed with LN. For study inclusion, the kidney biopsy must be interpreted as one of the following classes: Class 3, Class 3\u002F5, Class 4, or Class 4\u002F5.\n4. Treatment of LN with twice daily MMF as per the decision of the treating physician.\n\n   The subject will have taken MMF as prescribed by their treating physician for a minimum of 4 days (or 8 doses).\n5. Subject tolerates MMF as per the treating physician's opinion;\n6. Able to swallow MMF tablets and capsules;\n7. If subject is treated with belimumab, must be IV or SQ;\n8. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;\n9. Evidence of a personally signed and dated Informed Consent document and Assent document (as appropriate) indicating that the subject and a legally acceptable representative\u002F parent(s)\u002Flegal guardian has been informed of all pertinent aspects of the study.\n10. Parent or legal guardian must have a smart phone available and able to support the PLUMM smart phone application.\n11. Must be able to complete study questionnaires in English or Spanish.\n\nExclusion Criteria:\n\n1. Perceived or stated inability to adhere to the study protocol;\n2. Hypersensitivity to MMF or any component of the drug product;\n3. Presence of features (from SLE or other chronic disease) that a-priori suggest that the subject benefits from other therapies than that suggested or allowable by the study protocol; These disease features include but are not limited to severe, progressive, or uncontrolled hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.\n4. History of other kidney disease besides LN or prior to the diagnosis of SLE;\n5. Need for renal replacement therapy within 2 weeks from Baseline Subjects can have required short-term renal replacement therapy prior to Baseline, for example due to preceding acute kidney injury.\n6. Infections:\n\n   1. Untreated latent or active tuberculosis (TB);\n   2. Chronic infections requiring treatment;\n   3. A subject known to be infected with Human Immunodeficiency Virus (HIV), Hepatitis B;\n   4. Diagnosis of any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within 4 weeks prior to Baseline visit;\n   5. Any treated infections within 2 weeks of Baseline visit;\n   6. History of infected joint prosthesis with prosthesis still in situ;\n7. Blood dyscrasias, including:\n\n   1. Hemoglobin \\\u003C8.5 g\u002FdL or Hematocrit \\\u003C22%;\n   2. White Blood Cell count \\\u003C2.6 x 109\u002FL;\n   3. Neutrophil count \\\u003C1.2 x 109\u002FL;\n   4. Platelet count \\\u003C100 x 109\u002FL;\n   5. Lymphocyte count \\\u003C0.5 x 109\u002FL.\n8. 8\\) Estimated glomerular filtration rate \\[GFR\\] \\\u003C40 mL\u002Fmin\u002F1.73 m2 calculated using the CKiD U25 equation (see Appendix 4);\n9. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 times the upper limit of normal;\n10. Vaccinated or exposed to a live or attenuated vaccine within the 4 weeks prior to Baseline visit;\n11. History or current symptoms suggestive of lymphoproliferative disorders (e.g., Epstein Barr Virus \\[EBV\\] related lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorders, or multiple myeloma);\n12. Current malignancy or history of any malignancy with the exception of adequate treated or excised basal cell or squamous cell or cervical cancer in situ;\n13. Recent (within 4 weeks prior to Baseline visit) significant trauma or major surgery;\n14. Herbal supplements with pharmaceutical properties must be discontinued at least 1week prior to Baseline visit, unless there are sufficient data available regarding the duration of an herbal medication's pharmacokinetic and pharmacodynamic effects to allow a shorter or longer washout to be specified (e.g., 5 half-lives).\n15. Oral or intravenous cyclophosphamide must be discontinued 12 weeks prior to Baseline visit\n16. Use of prohibited prescription medication as listed in Appendix 3 within the specified time frame prior to Baseline visit\n17. Participation in other studies involving investigational drug(s) within 4 weeks or 5 half-lives (whichever is longer) prior to Baseline visit and\u002For during study participation; Exposure to investigational biologics should be discussed with the Sponsor.\n18. Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male subjects able to father children and female subjects of childbearing potential who are unwilling or unable to use two highly effective methods of contraception or are abstinent for the duration of the study;\n19. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.","ALL","8 Years","20 Years",{"count":384,"type":385},105,"ESTIMATED","INTERVENTIONAL",[388],"PHASE2","The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg\u002Fm2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0-12h) of MPA \\>60-70 mg\\*h\u002FL. The study goal is to determine the safety and efficacy of MMFPK compared to MMFBSA for the treatment of proliferative LN in subjects 8 to \\\u003C21 years.",[391],"Lupus Nephritis","2026-03-16",{"date":394,"type":395},"2026-03-18","ACTUAL",{"date":397,"type":395},"2024-06-07",{"date":399,"type":385},"2027-01",{"name":5,"class":6},19]